The proliferative action of ERa largely accounts for the carcinogenic activity of estrogens. By contrast, recent data show that ERb displays tumor-suppressor properties, thus supporting the interest to identify compounds that could increase its activity. Here, we show that histone deacetylase inhibitors (HDI) upregulated ERb protein levels, whereas it decreased ERa expression. Part of this regulation took place at the mRNA level through a mechanism independent of de novo protein synthesis. In addition, we found that, in various cancer cells, the treatment with different HDI enhanced the liganddependent activity of ERb more strongly than that of ERa. On the other hand, in MDA-MB231 and HeLa cells, the expression of ERs modified the transcriptional response to HDI. The use of deletion mutants of both receptors demonstrated that AF1 domain of the receptors was required. Finally, we show that ERb expression led to a dramatic increased in the antiproliferative activity of HDI, which correlated with a modification of the transcription of genes involved in cell cycle control by HDI. Altogether, these data demonstrate that the interference of ERb and HDAC on the control of transcription and cell proliferation constitute a promising approach for cancer therapy.
Introduction
It is well documented that the mitogenic action of estrogens is critical in the etiology and progression of human breast and gynecological cancers (Henderson et al., 1988) . The biological actions of estrogens are mediated via two distinct nuclear estrogen receptor (ER) proteins, ERa and ERb, which belong to a large conserved superfamily of nuclear receptors (Pettersson and Gustafsson, 2001 ).
The two ERs share a similar primary structure. The N-terminal A/B domain contains the ligand-independent transactivation function AF-1. The DNA-binding or C domain contains a dimerization interface that mediates cooperativity in DNA binding. The E/F domain is involved in ligand binding, dimerization, cofactor binding and transactivation through the transactivation function (AF-2). ERa and ERb differ mostly in the N-terminal A/B domain and to a lesser extent in the ligand-binding domain. These differences suggest that the two receptors could serve distinct actions.
The transcriptional activities of ERs rely on their interactions with transcription coregulators broadly defined as coactivators that increase transcriptional activation when recruited, and as corepressors that attenuate promoter activity. Several coregulators either possess histone acetyltransferase activity (HAT) or recuit histone deacetylase (HDAC), both enzymes being involved in chromatin remodeling (McKenna and O'Malley, 2002) and subsequent access of the transcriptional machinery to promoters. Several HDAC inhibitors (HDI) such as trichostatin A (TSA) have been shown to modify reversibly or irreversibly the balance between HAT and HDAC activities (Marks et al., 2000) . HDI induce growth arrest, differentiation, and/or apoptosis in a variety of transformed cell lines and inhibit tumor development in rodents (Cohen et al., 1999; Margueron et al., 2004) . Several studies in animal models have reported the efficacy of some of these inhibitors in blocking tumor growth (Marks et al., 2000) , mammary tumors in particular (Vigushin et al., 2001) . Phase I and II clinical trials are currently under way for several of these molecules (Kramer et al., 2001) to test whether HDI might provide an alternative therapeutic approach for the treatment of breast cancer.
The aim of the present study was to analyse the interferences between ERs and HDI on different parameters in human cancer cells. We report that ERa and ERb were differentially regulated by HDI at both the RNA and protein levels. HDI preferentially increased the estrogen-dependent transactivation of ERb as compared to ERa. On the other hand, ERb expression modulated the transcriptional effects of HDI on several genes involved in the control of cell proliferation. We propose that these effects could account, at least in part, for the synergistic effects of HDI and ERb on breast cancer cell proliferation.
Materials and methods

Materials
Propyl pyrazole triol (PPT) and diarylpropionitrile (DPN) were from Tocris. Estradiol-17b (E2) and TSA were from Sigma.
Cell culture Cells were maintained in media recommended by the ATCC supplemented with 10% fetal calf serum (FCS) and gentamycin. To wean off steroids, the cells were cultured in phenol redfree DMEM/F12 medium supplemented with 10% CDFCS (charcoal dextran-treated FCS) for 4 days.
Plasmids
The luciferase reporter plasmid ERE2-TK-LUC contains two copies of the consensus estrogen-responsive element (ERE) cloned upstream of the thymidine kinase promoter. CMV-ERa and CMV-ERb correspond to the wild type and mutant human ERa and ERb cDNAs cloned into CMV5 plasmid under the control of the cytomegalovirus (CMV) promoter. A CMV-Gal reporter was used as an internal control and corresponds to the b-galactosidase gene cloned into CMV5.
Transient transfection 3 Â 10 5 cells were plated in 12-well plates in phenol red-free DMEM-F12 supplemented with 10% CDFCS 24 h before transfection. Transfections were performed using lipofectamine according to the manufacturer's recommendations using 2 mg of luciferase reporter along with 150 ng of each expression vector and 0.5 mg of the internal reference reporter plasmid (CMV-Gal) per well. After overnight incubation, the medium was removed and the cells were placed into fresh medium supplemented with control vehicle (ethanol) or TSA. After 24 h, cells were harvested and assayed for luciferase activity on a Centro LB960 Berthold luminometer. b-Galactosidase was determined as previously described (Lazennec et al., 2001) .
Adenovirus infection
The adenoviruses Ad5, Ad-hERa, Ad-hERb used in this study and their propagation have been described previously (He et al., 1998; Lazennec et al., 2001) . The optimal infection conditions were determined for the different cell lines using a b-galactosidase encoding virus to determine the optimal multiplicity of infection (MOI).
RNA extraction and quantitative PCR Total RNA was extracted using the TRIzol reagent. For RT-PCR, 1.5 mg of total RNA was subjected to a reverse transcription step using the Omniscript Reverse Transcriptase kit (Qiagen, Valencia, CA, USA). Real-time PCR quantification was then performed using a SYBR Green approach (Light Cycler; Roche). For each sample, ER mRNA levels were corrected for HPRT mRNA levels (reference gene) and normalized to a calibrator sample. The primers for the ERa/b and HPRT mRNA have been published elsewhere (de Cremoux et al., 2002) .
Western blot analysis
Cells were resuspended in 10 mM Tris-HCl, pH 7.4, 1.5 mM EDTA, and 10% glycerol containing a cocktail of protease inhibitors. Then cells were lysed by cycles of freezing/thawing and the cellular debris were pelleted by centrifugation at 13 000 g for 20 min. Whole-cell extract proteins (30 mg) were subjected to SDS-PAGE followed by electrotransfer onto a nitrocellulose membrane. The blot was probed with anti-hERa (SRA-1000, Stressgen), hERb antibody (CWK-F12) (Lazennec et al., 2001) , cyclin E (Santa-Cruz) or p21 WAF1/CIP1 (Oncogene Research) at a 1:500 to 1:1000 dilution and then incubated according to the primary antibodies with anti-mouse or antirabbit IgG horseradish peroxidase conjugated antibodies (Sigma-Aldrich, St Quentin Fallavier, France) (1 mg/ml). An ECL kit (Amersham Pharmacia Biotech, Arlington, IL, USA) was used for detection.
Cell proliferation studies Cells were maintained for 5 days in 10% CDFCS phenol redfree medium and then seeded at 20 000 cells/well in 24-well dishes. Cells were infected overnight with the different viruses. The next morning, the medium was removed and replaced with fresh medium. Treatment with E2 or TSA began at the same time. After 4 days of treatment, the total cell DNA was quantified by diaminobenzoic acid assay as described earlier (Lazennec et al., 2001) .
Apoptosis
MDA-MB231 cells were plated in six-well plates (50 000 cells/ well) and infected 24 h later with adenoviruses (Ad5, Ad-hERa or Ad-hERb). After 48 h, cells were treated or not with E2 (10 nM) and/or TSA (50 ng/ml) for 2 days. Apoptosis was then quantified using the Cell death detection kit (Roche Molecular Biochemicals), according to the manufacturer's conditions and corrected using DNA quantification in separate wells treated in parallel.
Results
HDI differentially regulate the endogenous expression of ERa and ERb
We first wanted to determine how ERa and ERb RNA and protein levels were modulated by TSA in a physiological context. Endogenous ERa RNA found in MCF-7 cells was strongly downregulated by TSA, whereas the levels of ERb RNA were slightly induced (Figure 1a and b) . The regulation was also observed at the protein level for ERa (Figure 1a ), whereas no ERb protein could be detected in these cells (data not shown). To assess whether the modulation of ERa and ERb mRNA levels was direct, we used a synthetic inhibitor of protein synthesis (CHX) (Figure 1a and b). We observed that CHX was unable to block either ERa RNA downregulation or ERb upregulation by TSA, suggesting that the modulation of both RNA levels by HDI does not require de novo protein synthesis. To confirm that ERb expression was increased at the protein level, we used the OVCAR-3 ovarian cell line that expresses high levels of ERb. In these cells, both endogenous ERb RNA and protein levels were strongly increased upon TSA treatment (Figure 1c) , thus confirming the differential regulation of the two ERs upon inhibition of HDAC activity.
E2 and HDI synergistically activate ERb
We then analysed the effect of HDI on the transactivation of ERa and ERb in different cancer cell lines by transient transfection assays using an estrogen-responsive reporter construct ( Figure 2a ). The cell lines chosen were all ER-negative and subsequently transfected with an empty expression vector (CMV5) or with vectors encoding ERa or ERb. In MDA-MB231 breast cancer cells, TSA alone had a slight effect on the regulation of ERa activity by E2. By contrast, TSA increased by more than two-fold the E2-dependent activity of ERb. To assess whether this result could be generalized to other cell types, we performed the same experiments in HeLa (cervix), and HEK-293 (kidney) human cell lines (Figure 2a) . We observed the same general trend of greater activation for ERb than for ERa by TSA with a maximal effect in HeLa cells and an opposite effect of TSA on ERa and ERb transactivation in HEK-293 cells. Interestingly, in transfected cells, we also observed that ERb levels were upregulated by HDI treatment, whereas ERa levels were poorly affected, except in HEK-293 cells. This suggests that the increased expression of ERb upon HDI treatment is at least partially involved in the higher transactivation of the reporter.
To ensure that these regulations could also be detected on a natural E2-regulated gene, we performed the same experiment using the pS2 promoter fused to the luciferase reporter gene. As shown in Figure 2b , we obtained again a significant induction of ERb transactivation, whereas in parallel, ERa transcriptional activity was decreased upon TSA treatment. Finally, to assess that the synergism between ERb and HDAC inhibition was not specific of TSA, we used two other HDI structurally unrelated to TSA (sodium butyrate and SAHA). As shown in Figure 2c , these two HDI were also more potent to increase the activity of ERb in the presence of E2, than the one of ERa, confirming that ERb E2-dependent transactivation is more affected by HDI than that of ERa.
It was also of interest to assess whether the increased sensitivity of ERb to TSA was dependent or not on the concentration of hormone used in the assay. The E2 dose response performed in the absence or the presence of TSA showed that the preferential response of ERb to TSA was observed for concentrations ranging from 0.1 nM to 1 mM of E2 (Figure 3a) .
We then investigated whether the same preferential regulation of ERb also occurred with specific agonist of each receptor. We used PPT or DPN to specifically activate ERa and ERb, respectively (Harrington et al., 2003) . As obtained with E2, we noticed that TSA treatment increased only by 1.6-fold the activity of ERa in the presence of PPT, whereas the activity of ERb in the presence of DPN was increased by more than 6.5-fold (Figure 3b ). In the same line, we also analysed if TSA could modulate ERa and ERb activities in the presence of either pure or partial antiestrogens. As shown in Figure 3c , TSA treatment did not significantly modify the antagonist effect of the two types of antihormones on either ERa or ERb in conditions, where E2 effect was increased by 1.7-and 5.6-fold respectively. 
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Both ERa and ERb interfere with the transcriptional activity of HDI We then thought to investigate the transcriptional interference in the reverse way. In response to TSA, transcriptional activation of the thymidine kinase reporter occurred through Sp1-binding sites and is based on the inhibition of Sp1-recruited HDAC activity (Doetzlhofer et al., 1999) . We therefore analysed if the expression of ERs could modulate the TSA-regulation of the reporter. As shown in Figure 4b , expression of either wild-type ERa or ERb increased the transcriptional activation in response to TSA only in the presence of E2. This effect required the binding of the receptors to DNA since no modulation of TSA activity by ERs was observed on the reporter construct deleted of the ERE (data not shown). To define the role of the constitutive AF1 domain in the regulation of TSA activity by ERs, we used deletion mutants of both receptors (Figure 4a ). Interestingly, both in the absence or the presence of E2, the deletion of the A/B domain of ERa or ERb decreased by more than two-fold the level of TSA-induced reporter activity obtained with wildtype receptors (Figure 4b ). Similar results were obtained in MDA-MB231 cells (data not shown). This suggests that the modulation of HDI action by ERs requires the A/B domain. 
The combination of ER expression and HDI treatment inhibits cancer cell proliferation HDI are known to inhibit the proliferation of many cancer cells and to increase their apoptosis. It was thus of great interest to test whether the combination of ER introduction and HDI treatment could lead to a supraadditive inhibition of breast cancer cell proliferation. The ERs were introduced into HeLa (Figure 5a ) and MDA-MB231 (Figure 5b ) cells using the adenovirusbased approach. In HeLa cells, Ad5 or Ad-hERa cells exhibited a similar decreased growth in the presence of TSA (Figure 5a ). Introduction of ERb in HeLa cells reduced their basal proliferation and this was further amplified by TSA treatment (Figure 5a ). In MDA-MB231 cells (Figure 5b ), when ERa-expressing cells were treated with TSA, the growth inhibition observed was more important to that of Ad5 cells, in accordance with our previous results (Margueron et al., 2003) ( Figure 5b) . The results were even more striking when looking at ERb expressing cells, as addition of TSA strongly blocked cell proliferation (Figure 5b ). These data suggest that the combination of ERb and HDI treatment constitutes a powerful way to inhibit cancer cell proliferation. The question could be raised whether the decreased proliferation observed was due at least in part to an increased apoptosis. When treating cells with TSA, ERa and ERb displayed a more pronounced apoptosis than control cells ( Figure 5c ). As ERb cells do Estrogen receptors and HDAC inhibition V Duong et al not display a higher apoptosis rate compared to their ERa counterparts, it is likely that apoptosis is not the major reason accounting for the differential sensitivity in terms of proliferation of both types of cells to HDI.
To understand how ERa and ERb were amplifying the antiproliferative effect of TSA, we first analysed the expression of synthetic reporter constructs corresponding to genes involved in the control of cell proliferation, such as p21
, cyclin D1 and cyclin E (Figure 6a ). As shown in previous studies, HDI treatment increased the levels of p21 WAF1/CIP1 and decreased that of cyclin D1. By contrast, despite its antiproliferative activity, TSA strongly increased the transcription of cyclin E gene, which positively controls cell proliferation (Sambucetti et al., 1999) . Transfection assays in HeLa cells showed that, in the presence of ERb, TSA was both a better inducer of p21 WAF1/CIP1 promoter and a stronger inhibitor of cyclin D1 transcription than when ERa was expressed (Figure 6a ). Very interestingly, we also observed that ERb significantly antagonized the TSA regulation of the cyclin E reporter. Similarly, HDI treatment also increased an artificial construct containing an AP-1 response element (as a model for growth factor-regulated genes)
Ad5
Ad-hERβ Ad-hERα
Ad-hERβ Ad-hERα and, as in the case of cyclin E, ERb strongly diminished the induction by TSA.
We next measured the regulation of cyclin E and p21 WAF1/CIP1 endogenous genes by HDI at the protein level (Figure 6b and c) . We observed that cyclin E levels were lower in the presence of ERb compared to ERa cells (Figure 6b ). In addition, cyclin E expression was upregulated by TSA only in ERa expressing cells. Concerning p21
, we noticed that its expression was better induced by TSA in ERb expressing cells compared to ERa cells. Altogether, these data suggest that the differential effects of ERb on HDI-regulation of genes involved in proliferation could account for the higher antiproliferative action of TSA in cells expressing this receptor.
Discussion
Research performed over the last decade has highlighted the role of HDI as modulators of transcriptional activity and as a new class of therapeutic agents. The aim of this study was to determine how HDI influenced the expression and transcriptional activity of ERa and ERb and how the expression of these receptors modulated the antiproliferative properties of HDI.
Our data first demonstrate a differential effect of HDAC inhibition on ERa and ERb expression. Indeed, in cells expressing high levels of ERa such as MCF-7 cells, ERa mRNA and protein are strongly reduced as previously shown by other studies (Stevens et al., 1984) . However, the effects of HDI on ERa levels are complex since in ERa-negative cells, we observed that TSA treatment reactivated ERa expression (data not shown), which is in agreement with previous studies (Yang et al., 2000) . Recent work has demonstrated that this upregulation in ERa-negative cells involves histone hyperacetylation of ERa promoter and the release of HDAC1 and MeCP2 from ERa promoter (Sharma et al., 2005) . On the contrary, ERb expression was upregulated in all cell lines (ERa-negative or positive) that we tested. ERb protein enhanced expression by HDI is due at least in part to a direct increase in ERb RNA levels, but could also result from the regulation at the posttranscriptional level.
We also show that HDI increase the ligand-induced activity of ERb in a more pronounced manner compared to the effects observed for ERa on both synthetic and natural promoters, when using different HDI. Very interestingly, the combination of both HDI and E2 enables ERb to be at least equal or more active than ERa. This is definitely important as ERb is generally a twice less potent transactivator than ERa in the presence of estrogens. The lower transactivation ability of ERb has been reported by several groups both on synthetic and endogenous genes (McInerney et al., 1998; Cowley and Parker, 1999; Lazennec et al., 2001 ). In the situation in which AF-1 is important for transactivation, ERa is a better activator than ERb, whereas both receptors display equivalent potencies when only AF-2 is required. A supra-additive action of HDI and nuclear receptor ligands has been reported for ERa (Ruh et al., 1999) and also for PR (Liu et al., 1999) , retinoid receptors (Minucci et al., 1997) , PPARg (Fajas et al., 2003) , AR (Shang et al., 2002) and TR (Stanley and Samuels, 1984) , suggesting that this is a general phenomenon.
The enhanced ERb activity upon HDI treatment involves certainly an increase of ERb protein levels. However, we believe that regulatory events controlling the transcriptional activity of the receptor could also take place. These probably include effects on chromatin structure, as suggested by the group of Lee Kraus (Cheung et al., 2003) . Using in vitro transcription assays, these authors have reported that ERb was a weak activator on chromatin templates, whereas it efficiently increased transcription on naked DNA. Moreover, the addition of TSA only weakly affected ERa activity on chromatin templates but strongly enhanced the one of ERb (Cheung et al., 2003) . This difference has been attributed to the fact that ERa (but not ERb) contains a transferable activation function in its A/B region that facilitates transcription with chromatin templates.
In addition, it is tempting to speculate that posttranslational modifications could differentially modulate ER activity in response to HDI treatment. Indeed, several studies have shown that nuclear receptors could be acetylated, which in turn could modulate their transactivation ability. This is the case of ERa and AR in D domain (Fu et al., 2000; Wang et al., 2001) . It should be noted that the acetylated motif in ERa is poorly conserved in ERb, suggesting that the two receptors could be differentially modified. However, using in vitro interaction assays, we have not observed a different ability of the two ER to interact with class I or II HDACs (data not shown). The present work demonstrates that the cross-talk also exist in the reverse way since expression of ERs strongly modulates the transcriptional response observed upon TSA treatment. One interesting observation concerning the regulation of an ERE-containing reporter is that this synergy with HDI required the A/B domain of the receptors. Most notably, in the absence and the presence of E2, the AF1 deleted version of the two receptors exhibited a strong repressive activity on the regulation by TSA and it would be valuable to understand the underlying mechanisms of this negative regulation.
From a clinical point of view, several studies have shown that ERb expression was decreased when cells turn cancerous and suggest that ERb could play a tumor suppressor role. This holds true for breast, ovary, colon, and prostate cancers (Pujol et al., 1998; CampbellThompson et al., 2001; Roger et al., 2001 ). We and others have shown that ERb could inhibit the proliferation and invasion of breast, and prostate cancers, while increasing apoptosis (Lazennec et al., 2001; Cheng et al., 2004; Paruthiyil et al., 2004) . In addition, several studies have shown that ERa expressing cancer cells were more sensitive to HDI than ERa-negative cells (Margueron et al., 2003; Jang et al., 2004) . On the other hand, as shown by our observation and recent data, ERb and to a lesser extent ERa strongly enhanced the Estrogen receptors and HDAC inhibition V Duong et al antiproliferative action of HDI (Jang et al., 2004) . In addition, both receptors enhanced the proapoptotic action of HDI. The greater effects of ERb on proliferation compared to ERa could be the result of distinct cell cycle gene regulations. Indeed, we showed that HDIinduced p21 WAF1/CIP1 promoter activity was higher in ERb compared to ERa cells. On the other hand, the decrease of cyclin D1 transcription by TSA was stronger when ERb was expressed instead of ERa. In addition, the positive effects of HDI on cyclin E promoter and on global AP-1 activity were lower in ERb compared to ERa expressing cells. Altogether, these data suggest that the differential effects of ERb and ERa on genes involved in cell proliferation account for the synergistic inhibition of proliferation by ERb and HDI. The higher sensitivity of ERb to HDI compared to ERa and the fact that HDI differentially regulate the expression of endogenous receptors could be a very valuable result. It would thus be of great interest to potentiate the overall tumor-suppressor properties by increasing its expression and activity to design new strategies in the future. HDI are currently tested in several clinical trials at phase I or II (Vigushin and Coombes, 2002) and future work will determine whether part of their effects in cancers could arise from the increased expression of ERb.
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